Ofatumumab
- Generic Name
- Ofatumumab
- Brand Names
- Arzerra, Kesimpta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 679818-59-8
- Unique Ingredient Identifier
- M95KG522R0
- Background
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and...
- Indication
Ofatumumab is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
...
- Associated Conditions
- Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL) - Refractory, Clinically Isolated Syndrome (CIS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS), Progressive Chronic Lymphocytic Leukaemia (CLL), Recurrent Chronic Lymphocytic Leukaemia (CLL)
- Associated Therapies
- -
Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-05-11
- Last Posted Date
- 2018-05-25
- Target Recruit Count
- 10
- Registration Number
- NCT01352312
- Locations
- 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2011-04-06
- Last Posted Date
- 2020-07-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT01329900
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia
- First Posted Date
- 2011-03-14
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 122
- Registration Number
- NCT01313689
- Locations
- 🇬🇧
Novartis Investigative Site, Oxford, United Kingdom
Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma
- Conditions
- Ann Arbor Stage III Grade 1 Follicular LymphomaAnn Arbor Stage III Grade 3 Follicular LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaGrade 3a Follicular LymphomaAnn Arbor Stage IV Grade 1 Follicular LymphomaAnn Arbor Stage IV Grade 2 Follicular LymphomaAnn Arbor Stage IV Grade 3 Follicular Lymphoma
- Interventions
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 135
- Registration Number
- NCT01286272
- Locations
- 🇺🇸
Springfield Memorial Hospital, Springfield, Illinois, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸Saint Helena Hospital, Saint Helena, California, United States
Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2010-12-20
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Registration Number
- NCT01263418
Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy
- First Posted Date
- 2010-12-13
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT01258933
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
GIMEMA CLL0809 Study (BendOfa)
- Conditions
- Interventions
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2019-01-25
- Target Recruit Count
- 49
- Registration Number
- NCT01244451
- Locations
- 🇮🇹
Azienda Sanitaria di Bolzano - Ospedale Centrale - Ematologia e Centro TMO, Bolzano, Italy
🇮🇹Messina Divisione di Ematologia - Azienda Ospedaliera Ospedali Riuniti "Papardo Piemonte", Messina, Italy
🇮🇹Policlinico di Careggi, Università delgi studi di Firenze, Firenze, Italy
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2023-04-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT01243190
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2010-11-11
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 43
- Registration Number
- NCT01239394
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL
- Conditions
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2015-06-25
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 71
- Registration Number
- NCT01217749
- Locations
- 🇺🇸
The Ohio State University, Columbus, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.